CMS Entry id: 2709 | Channel: Blog landing page | Template: blog/index

Login
Facebook YouTube Twitter Linkedin
Facebook YouTube Twitter Linkedin

Blog

What is the value of objectively measuring emotional bias?

A negative, perceptual bias is associated with the onset and maintenance of mood disorders, and is therefore a therapeutic avenue of interest. Here we will discuss the launch of an objective assessment of emotional bias as a potential biomarker of mood. 

Bringing a drug to market: How do we find and monitor suitable patients?

What will happen when we eventually develop a treatment that halts the development of early Alzheimer’s disease? Being first-in-class, pharmacovigilance post-marketing will be vitally important to ascertain the long-term effects of the drug: both positive and negative. We need to be prepared for a breakthrough and pre-emptively identify technologies which can find the right patients likely to benefit from the drug and monitor treatment effects in the real world. 

How can you measure behavior more accurately in your clinical trials?

Drug development typically relies upon clinical endpoints established within very controlled laboratory environments. Digital health technologies now provide the opportunity to transition data collection from the clinic into people’s personal lives, thereby providing more accurate conclusions about how a compound can influence their day-to-day life. 

Does using digital health in clinical trials generate real-world outcomes?

High-frequency digital health assessments can not only characterize clinically-relevant data as it occurs in real-time, but capture this information within the patient’s home environment. Therefore, digital health platforms provide an ecologically valid data source which directly maps on to an individual’s daily functioning and real-world outcomes. 

Can digital health reduce the treatment burden on patients?

Comprehensive neuropsychological testing typically takes hours to complete, which can be mentally and physically burdensome for patients. Furthermore, the travel required and overall time-commitment to undergo these procedures within a clinic can result in decreased study compliance. Together these factors can confound conclusions concerning treatment efficacy. Here we will discuss how digital health can reduce these burdens when implementing therapeutic interventions to improve patient outcomes. 

Four reasons to use digital health in your clinical trials

In the first of our digital health series we will outline what the term means, and the opportunities offered, within the context of clinical trials in psychiatry. 

How can digital health improve the signal-to-noise ratio in your clinical trials?

The contemporary framework for designing clinical trials is to build a comprehensive cognitive profile of the patient population from thorough but infrequent assessments. However, this framework struggles to capture the daily fluctuations in mood and cognition that many individuals with psychiatric disorders experience. Here we will discuss how the advent of digital health offers the opportunity to capture a more holistic representation of patients’ cognitive function from high-frequency assessments.

NeuroVocalix platform ready for clinical trials

NeuroVocalix enables novel voice-based cognitive assessments to be delivered directly to patients through mobile and tele-health platforms, helping to improve outcomes in clinical trials, aid clinical decision-making and play an important role in the management of long-term conditions such as chronic pain.

What is the optimal approach for using digital cognitive biomarkers in clinical trials?

Digital cognitive biomarkers are typically active or passive: but which approach enhances clinical trial success? Here we will define how active and passive cognitive biomarkers function in clinical trials, to conclude their optimal application.

What are digital cognitive biomarkers and why are they useful?

Biomarkers are important for the detection of disease-relevant information to help recruit, stratify and monitor patients, and to evaluate the safety and efficacy of compounds. Here we’ll discuss what digital biomarkers are and how they offer an opportunity to revolutionize research and drug development in psychiatric and neurological disorders. 

How can employers promote mental health at work?

Mental wellbeing is integral to the health and functioning of the workforce, the compromise of which can have serious social and financial ramifications - but what actions can employers take to promote mental wellbeing?  

Healthy Amplified launch new population health platform with CANTAB technology

Healthy Amplified are using CANTAB® technology to expand their population health platform offering to adults. 

Neural Network classification of longitudinal cognitive data for prediction of individual-level chan

For the first time, Neural Network classifiers have been applied to changes in CANTAB PAL performance between baseline and 10 months to accurately predict the development of MCI at 20 months. Dr Elizabeth Baker, Statistical Scientist at Cambridge Cognition, presented the novel findings at AAIC 2018

CANTAB BrainHealth offers benefits for healthcare professionals, employers and employees

We caught up with brain health and workplace mental performance consultant, Dr Jenny Brockis, on how tools like CANTAB BrainHealth can be used to promote mental wellbeing at work. 

CANTAB technology selected for world’s largest dementia study

We are pleased to announce our partnership with Dementias Platform UK (DPUK), the world’s largest study group in dementia research formed to accelerate the development of effective, and ultimately preventative, treatments for diseases such as Alzheimer’s.

New product to improve workplace mental health

We are very pleased to announce a planned new software product to assess mental health and wellbeing at work, CANTAB BrainHealth™.

New client signs with Cognition Kit software

We’re delighted to announce a new $0.5m contract with a major pharmaceutical company for the use of our Cognition Kit digital health software in a clinical trial.

Pen-and-paper vs. computerised testing: which method do older adults prefer?

Exciting new research shows not only that web-based cognitive assessments are suitable for older adults but, for many, computerised assessments are actually preferable to traditional pen-and-paper tasks. 

Cognition Kit wearable technology demonstrates high compliance among patients with major depressive

​At the 2017 International CNS Summit in Boca Raton, Florida, we were pleased to release the positive results from a pilot study into the evaluation of cognition and mood using wearable technology in patients with MDD.

Wearable devices: the future for near-patient testing?

Cognition Kit and Takeda have collaborated to deliver high frequency assessments of mood and cognition in major depressive disorder, using the Apple Watch. 

Join us at the CNS Summit 2017

Cambridge Cognition are attending the Collaborating for Novel Solutions (CNS) Summit: 16th-19th November 2017. 

Speech recognition and online assessments: the future for clinical trials in Alzheimer's disease?

New data demonstrates possibility for speech recognition and online assessments to enhance clinical trials in Alzheimer’s disease.

Award of funding to develop novel digital health system

A new system being developed by Cambridge Cognition with Innovate UK funding will provide a non-invasive, inexpensive means of accurately monitoring levels of pain by combining artificial intelligence technology and cognitive neuroscience.

Alzheimer's research technology showcase - AAIC 2017

Showcasing a range of digital neurotechnologies to improve the research, diagnosis and treatment in Alzheimer's disease.

Feasibility of automated voice based cognitive assessment on a consumer voice platform

Exploring the use of automated voice based cognitive assessments on consumer voice platforms.

Cognition and Alzheimer's Technology at AAIC 2017

Cambridge Cognition is attending the Alzheimer's Association International Conference in London.

Cambridge Cognition CSO named in Top 40 Healthcare Transformers

Company CSO honoured at this year's ceremony celebrating leading health-tech innovators.

Five ways digital health tools can help everyday brain health

Dr Jenny Barnett, Chief Scientific Officer for Cambridge Cognition looks at how digital innovations are helping our brain health.

Five reasons brain health is primed for digital innovation

Dr Jenny Barnett, Chief Scientific Officer for Cambridge Cognition examines the power that digital innovation has to change the way we look at brain health.

Takeda and Cognition Kit partner to pilot wearables in patients with Major Depressive Disorder (MDD)

Takeda Pharmaceuticals U.S.A. and Cognition Kit Limited announce a collaboration to pilot the use of a specially designed app on an Apple Watch wearable to monitor and assess cognitive function in patients with Major Depressive Disorder (MDD).

web-based testing, wearables, voice recognition, virtual clinical trials, transdiagnostic, test-retest, technology, swm, subjective measures, stigma, spatial planning, social cognition, smartphones, set-shifting, schizophrenia research, schizophrenia, rvp, rule learning, research funding, remote testing, regulations, recruitment, real-world assessments, prodromal, pro-cognitive, presenteeism, precision psychiatry, pre-clinical, pharmacovigilance, personalised medicine, patient-centric, patient screening, patient recruitment, parkinson's disease, pal, ots, opinion piece, occupational health, objective measures, novel, normative data, neurotech, neuroscience, near-patient testing, multiple sclerosis, ms, modelling, mental wellbeing, mental health, mci, major depression, machine learning, lifespan, inpatients, ied, high frequency, healthcare, ert, episodic memory, epidemiology, emotion recognition, efficacy, ecological momentary assessments, ebt, ebbinghaus, early alzheimer's disease, drug development, dopamine, digital tools, digital health, depression, dementia, cognitive testing, cognitive science, cognitive safety, cognitive impairment, cognitive function, cognitive dysfunction, cognitive deficits, cognitive biomarkers, cognitive assessment, cognition kit, cognition, cns summit, clinical trials, clinical trial, clinical symptoms, cias, cgt, cantab research grant, cantab for clinical trials, cantab, brain health, biomarkers, awards, automatic speech recognition, attention, alzheimer's disease, affective cognition, absenteeism,